Alonso Krangle LLP Alerts Fosamax Users to New Study Linking Long-Term Use of Fosamax And Other Bisphosphonates, to An Increased Risk of Atypical Thigh Fractures

According to New Research Published in the Archives of Internal Medicine, Risk of Atypical Femur Fractures Increases the Longer a Patient Uses Bisphosphonates, Such as Fosamax

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Alonso Krangle LLP - Fighting for victims of personal injury cases due to harmful drugs is alerting Fosamax users to a new study confirming the association between the drug and femur fractures.

Alonso Krangle LLP - Fighting for victims of personal injury cases due to harmful drugs is alerting Fosamax users to a new study confirming the association between the drug and femur fractures.

Alonso Krangle LLP is currently offering FREE Fosamax lawsuit evaluations to anyone who suffered a femur fracture while using this drug.

Melville, NY (PRWEB) May 24, 2012

Alonso Krangle LLP, a national law firm focused on fighting for the rights of serious personal injury victims of harmful drugs, are alerting Fosamax users to a new study confirming the association between atypical femur fractures and long-term use of Fosamax and other bisphosphonates. According to the study, which appears online in the Archives of Internal Medicine, the likelihood that a patient will experience an atypical femur fracture increases the longer they use bisphosphonates like Fosamax.

Alonso Krangle LLP is currently offering FREE Fosamax lawsuit evaluations to anyone who suffered a femur fracture while using this drug. To discuss a potential lawsuit claim with one of the experienced and compassionate Fosamax side effects lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

According to the Archives of Internal Medicine, researchers in Switzerland looked at 477 patients, aged 50 and older, who were hospitalized with a femoral fracture. Of those patients, 39 had atypical fractures, a type of thigh fracture that can occur in the absence of a major leg injury. The other 438 patients in the study sustained a classic thigh fracture. These groups were compared with 200 people without femoral fracture. According to the report, 82 percent of the patients with atypical fractures had been treated with bisphosphonates, like Fosamax, compared with about 6 percent of the patients with classic fractures. [archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2012.1827]

When the study authors compared duration of bisphosphonate treatment versus no treatment, they found that the odds ratio for an atypical fracture versus a classic fracture was 35 to 1 for less than two years of treatment, 46 to 9 for two to five years of treatment, 117 to 1 for five to nine years of treatment, and 175 to 7 for more than nine years of treatment.

The study authors concluded that the association between bisphosphonate treatment and the occurrence of atypical femur fractures is highly likely, and that the duration of bisphosphonate treatment significantly correlates with the rising risk.

Fosamax, marketed by Merck & Co., is approved to treat osteoporosis and other bone weakening diseases. Other bisphosphonates used in the treatment of osteoporosis include Actonel, Boniva, Didronel, Reclast and Skelid. In October 2010, the FDA ordered the makers of Fosamax and other bisphosphonates to add information about the risk of atypical femur fractures to the “Warnings and Precautions” section of their labels. The FDA ordered the label change after a study involving over 300 women who sustained such fractures found that 94 percent had taken a bisphosphonate. Most had been on the drugs for five years or more. [fda.gov/Drugs/DrugSafety/ucm229009.htm]

Since the FDA mandated the label change, hundreds of women throughout the country have filed Fosamax femur fracture lawsuits, many of which are pending in a multidistrict litigation in U.S. District Court, District of New Jersey before the Honorable Garrett E. Brown, Jr. (“MDL No. 2243). Additional Fosamax lawsuits, including those alleging the drug caused femur fractures, have been designated a mass tort (In re: Fosamax Litigation - No. 282 NJ. Super. Ct.) in the Superior Court of New Jersey, Law Division, Atlantic County.

Alonso Krangle LLP offers free lawsuit evaluations to any Fosamax user who suffered a femur fracture that could be associated with long-term use of this drug. To discuss a potential claim with one of the experienced and compassionate Fosamax femur fracture lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical malpractice, qui tam/whistleblower actions, employee rights, and consumer fraud cases. A national law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and plans to open additional locations in New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.

Contact:
Alonso Krangle LLP
445 Broad Hollow Road
Suite 205
Melville, New York 11747
Toll-FREE 1-800-403-6191
Tel: 516-350-5555
Fax: 516-350-5554


Contact